Phase 3 clinical trial result of Hanmi Pharm’s ‘Rovelito’ registered at intern. journal

Published: 2016-11-11 11:22:46

Updated: 2016-11-11 11:22:46

The Phase 3 clinical trial result of Hanmi Pharm’s hypertension and hyperlipidemia complex ‘Rovelito’ was registered at a SCI-level international academic journal.

On the 9^th, Hanmi Pharm announced the Phase 3 clinical trial result of its hypertension and hyperlipidemia complex ‘Rovelito’ was registered at the international academic journal Clinical Therapeutics(Volume 38, Number 10, 2016) on ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.